Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia
Launched by NATIONAL LIVER INSTITUTE, EGYPT · Jan 24, 2024
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
Unconjugated hyperbilirubinemia is one of the most common conditions in neonates. Although conventional treatment, phototherapy and/or exchange transfusion, is effective, both modalities are associated with several side effects. High levels of unconjugated hyperbilirubinemia causing direct serious brain injury, in the form of acute bilirubin encephalopathy which may progress to kernicterus (chronic bilirubin encephalopathy) with classically characterized permanently extrapyramidal movement disorders of dystonia, choreoathetosis or both, hearing loss due to auditory neuropathy spectrum, and ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Neonates with total serum bilirubin (TSB) exceeding the 40th percentile track for age as per the hour-specific bilirubin nomogram of the American Academy of Pediatrics (AAP)
- • Neonates who have indirect hyperbilirubinemia, not indicated for exchange transfusion.
- Exclusion Criteria:
- • Neonates submitted to blood transfusion.
- • Neonates indicated for exchange transfusion
- • Associated congenital anomalies.
- • Co-morbidities such as sepsis, pneumonia or respiratory distress.
- • Neonates whom their mothers received phenobarbitone during the third trimester
About National Liver Institute, Egypt
The National Liver Institute (NLI) in Egypt is a leading research and clinical institution dedicated to advancing the understanding and treatment of liver diseases. Renowned for its commitment to excellence in hepatology, the NLI conducts innovative clinical trials aimed at evaluating new therapies and improving patient outcomes. With a multidisciplinary team of experts, state-of-the-art facilities, and a strong focus on translational research, the institute plays a pivotal role in shaping liver health policies and enhancing clinical practices in the region. By fostering collaboration with international research entities, the National Liver Institute is at the forefront of liver disease research and education in Egypt and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shibīn Al Kawm, Menoufia, Egypt
Patients applied
Trial Officials
Heba S. Sallam, specialist
Principal Investigator
Al-Dalangat Central Hospital, Beheira, Egypt
Hala H. Elsaeed, professor
Study Chair
National liver institute. Menoufia university, Egypt
Mohsen H Hussein, professor
Study Chair
National liver institute. Menoufia university, Egypt
Hanaa A. El- Alraby
Study Director
National liver institute. Menoufia university, Egypt
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported